Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Top Cited Papers
- 1 October 2018
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 24 (10) , 1504-1506
Abstract
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19– relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.Keywords
This publication has 21 references indexed in Scilit:
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- New development in CAR-T cell therapyJournal of Hematology & Oncology, 2017
- Fully human CD19-specific chimeric antigen receptors for T-cell therapyLeukemia, 2017
- PureCN: copy number calling and SNV classification using targeted short read sequencingSource Code for Biology and Medicine, 2016
- XLF deficiency results in reduced N-nucleotide addition during V(D)J recombinationBlood, 2016
- CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticityNature Communications, 2016
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyBlood, 2016
- Catch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesComputational and Structural Biotechnology Journal, 2016
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyCancer Discovery, 2015
- rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq dataProceedings of the National Academy of Sciences of the United States of America, 2014